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Abstract
SAPHO syndrome is an entity that associates musculoskeletal disorders with dermato-
logical alterations. The most characteristic clinical manifestation of the SAPHO syndrome 
is pain in the anterior chest wall, due to the involvement of the sternoclavicular and 
costochondral joints. The etiology of SAPHO syndrome is unclear. The treatment is not 
protocolized. Nonsteroidal anti-inflammatory drugs (NSAIDs), sulfasalazine, systemic 
corticosteroids, colchicine, methotrexate, and antibiotics such as tetracyclines have been 
used with varying results. The use of bisphosphonates has been described as effective. 
Biological therapy also seems to be effective. More trials with these drugs are needed to 
evaluate their effectiveness against this disease and to establish the number of doses, the 
amount, and the interval between them. In this chapter we describe the case of a patient 
with SAPHO syndrome who had a good response to oral alendronate.
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1. Introduction
SAPHO syndrome is an entity that associates musculoskeletal disorders with dermatological 
alterations, which may appear simultaneously or successively throughout a patient’s life. The 
term is an acronym for the most common manifestations such as synovitis, acne, palmoplan-
tar pustulosis, hyperostosis, and osteitis (Table 1). Bone lesions may present without relation 
to the appearance of cutaneous lesions.
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2. Etiology
The etiology of SAPHO syndrome is unclear. It is thought that it may have a multifacto-
rial origin where genetic, environmental, immunological [1], and infectious causes intervene. 
Some bacteria, such as the Bacillus Propionibacterium acnes, could act as a triggering factor [2]. 
However, the possible pathogenic role of this or other germs in a genetically predisposed 
patient has not been proven.
3. Epidemiology
Its prevalence is unknown, and it can be described in different ways (Table 2). A few cases 
have been reported in Spain to date. It usually occurs in childhood and adolescence and usu-
ally affects to the female gender.
A patient with SAPHO syndrome who had a good response to oral alendronate has been 
described, although this is not the first choice recommended for treatment (there are a few 
reports in the medical literature).
– Pseudoseptic acute arthritis and palmoplantar pustulosis
– Arthro-osteitis with palmoplantar pustulosis
– Manubrium-sternal arthritis and pustular psoriasis
– Symmetric multifocal chronic osteomyelitis
– Bilateral clavicular osteomyelitis with palmar and plantar pustulosis
– Chronic sclerosing osteitis
– Chronic multifocal osteomyelitis of unknown etiology
– Skeletal muscle syndromes associated with acne
– Pustular palmoplantar arthritis
– Hyperostosis of the sternal manubrium
– Recurrent hyperostosis of the mandible
– Bone lesions in palmoplantar pustulosis
– Sternocostoclavicular hyperostosis
– Sternocostoclavicular arthro-osteitis
Table 2. Synonyms of the SAPHO syndrome.
– Synovitis
– Acne
– Palmoplantar pustulosis
– Hyperostosis
– Osteitis
Table 1. Types of SAPHO syndrome.
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4. Literature review
The SAPHO syndrome is a rare entity that was first described in the 1980s [3]; since then 
many cases have been diagnosed in different regions, and it seems to maintain a certain geo-
graphic distribution, in which an increase in prevalence in Central European countries [4]. 
The syndrome can appear at any age, but it usually occurs in childhood and adolescence 
and usually affects the female gender [5]. Many authors have questioned the SAPHO syn-
drome as an independent entity since its discovery [6], although nowadays it seems that it 
is widely accepted, given its clinical and radiological characteristics that differentiate it from 
other diseases. Its physiopathology remains to be clarified. In the literature there are few 
cases described which hinder the development of controlled clinical trials to find an adequate 
treatment. Current treatments and their benefits are based on personal experiences [7]. In 
most cases NSAIDs manage to control the pain and inflammation of the affected joints, but 
cases in which this medication is not effective pose a difficulty for medical staff. Intravenous 
bisphosphonates, such as pamidronate and zoledronate, seem to be the most effective drugs 
due to the experiences described to date [8]. However, a suitable dosage has not yet been 
found. It is also being tested with another type of medication such as TNF-α antagonists 
[9, 10], which may be effective, but more studies and a larger number of patients are needed 
in order to obtain significant results.
5. Clinical case
The case of a 45-year-old woman who came for consultation due to costal pain and in the 
right renal fossa is presented. The pain was continuous, did not give in to rest, and did 
not increase with exercise; it was not related to any trigger, and she had it for 3–4 months. 
Any micturition syndrome or fever was not reported. She had not had any weight loss. 
The patient was a smoker [11] and had a history of hypercholesterolemia, renal lithiasis, 
osteoporosis in treatment with calcium/vitamin D, and palmoplantar psoriasis on treat-
ment with acitretin.
On the physical examination, pustule-erythematous, confluent lesions were found in the 
palms of both hands and on both soles of the feet. In addition, although she described it 
as costal, she presented localized pain in the sternoclavicular and chondrosternal region 
that increased to acupressure. She also had pain in the right renal fossa with a positive 
percussion fist.
Before these findings, various tests such as hemogram, biochemistry, coagulation, sys-
tematic urine, and chest X-ray were requested, with normal results. SVS, autoimmunity, 
and HLA-B27 were negative. Chest and abdomen CT were requested with the following 
report: probable areas of atelectasis/fibrous tracts in both lung bases; small bilateral renal 
cortical cysts; nonobstructive right renal lithiasis; arteriosclerosis of the aortoiliac axis; 
apparent increase of density of the subcutaneous at the level of the interlabial cleft, to 
be assessed in the clinical context of the patient; and degenerative alterations in the axial 
skeleton.
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A bone densitometry was performed, showing a T-score of −2.6 in the lumbar spine (L1–L4), 
compatible with osteoporosis. There was also a study in her neck, trochanter and total femur 
compatible with osteopenia.
Before the clinical suspicion, a bone scan [12] was requested. It showed a pathological focus 
on the right sternoclavicular joint, compatible with SAPHO syndrome, with hyperostosis of 
the joint (Figure 1).
Treatment was established with colchicine 0.5 mg 1/24 h. Methotrexate 15 mg IM/week (the 
Mantoux-Booster test was previously requested and serologies for HBV, HCV, and HIV that 
were negative): folic acid one tablet 1 day after the administration of methotrexate and alen-
dronate one tablet/week. Treatment with oral bisphosphonates was decided [13] despite the 
scarce records in the literature (agreed with the patient who did not want intravenous treat-
ment and opted for oral treatment). This dose and frequency of administration were decided 
since it is the one used in the treatment of postmenopausal osteoporosis.
At 6 weeks, the patient was reevaluated and presented an almost total decrease in sternocla-
vicular pain and a marked improvement in the palmoplantar lesions.
Figure 1. Hyperostosis on the right sternoclavicular joint, compatible with SAPHO syndrome, can be seen.
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6. Clinic
SAPHO syndrome is an entity that associates musculoskeletal disorders with dermatological 
alterations (Table 3).
The most characteristic clinical manifestation of the SAPHO syndrome is pain in the ante-
rior chest wall, due to the involvement of the sternoclavicular and costochondral joints. 
Less commonly, the sacroiliac, intervertebral, or peripheral joints are affected. It could also 
affect the jaw. It is usually presented symmetrically, bilaterally, and in outbreaks. In adults, 
disease predominates in the sternocostoclavicular region (65–90% of patients). All the com-
ponents of the anterior chest wall might be affected. The second affected region is the spine 
(33% of cases), mostly at the dorsal level. Nonspecific spondylitis, osteosclerosis of one or 
more vertebral bodies, and paravertebral ossifications could be observed. Ninety-two per-
cent of patients have arthritis with involvement their knees, hips, ankles, feet, and hands.
1. Chronic multifocal relapsing osteomyelitis
  Generally sterile
  With/without coccyx affection
  With/without skin affection
2. Acute/subacute/chronic arthritis in addition to:
  Palmoplantar pustulosis
  Pustular psoriasis
  Severe acne
3. Sterile osteitis in any localization in addition to
  Palmoplantar pustulosis
  Pustular psoriasis
  Vulgar psoriasis
  Severe acne
Table 3. Diagnostic criteria: one of the three presentations is enough for diagnosis.
Figure 2. Inflammatory pustules with erythema that affect palms of hands.
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In children it usually affects to the long bones such as the tibia and femur, clavicle, and lum-
bar spine.
Skin involvement is more variable and includes palmoplantar pustulosis, acne conglobata or 
fulminating, suppurative hidradenitis, dissecting cellulitis, or pustular psoriasis. The most 
predominant is palmoplantar pustulosis, which is characterized by inflammatory pustules, 
Figure 3. Pustular lesions, symmetric, with desquamation that affects the soles of the feet.
– Acne-associated syndrome
– PAPA syndrome
– PASH syndrome
– Arthritis associated with hidradenitis suppurativa
– Follicular occlusion triad
– Behçet disease
– Minocycline-induced autoimmune syndromes
– Isotretinoin side effect
– Pustular psoriasis
– Sneddon-Wilkinson disease
– Pustulotic arthro-osteitis
– Acquired hyperostosis syndrome
– Chronic recurrent multifocal osteomyelitis
– Diffuse sclerosing osteomyelitis of the mandible
– Majeed syndrome
– Nonbacterial osteitis
– Tuberculous spondylitis
– Secondary syphilis
– Primary bone tumors
– Metastatic tumors
Table 4. Differential diagnosis of SAPHO syndrome.
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symmetric, and sterile, with erythema and desquamation, which affect palms of the hands 
(Figure 2) and soles of the feet (Figure 3). The pathogenesis of the disease remains unknown, 
and there is still a debate about whether palmoplantar pustulosis is a variant of psoriasis or 
a distinct condition.
The SAPHO syndrome could present several clinical manifestations and therefore originate 
different differential diagnoses (Table 4). This is very important in neoplastic disease context, 
since it is necessary to avoid errors in the diagnosis that lead to aggressive treatment in a dis-
ease that it usually develops benign.
7. Diagnosis
The diagnosis is basically clinical and is complemented by imaging tests. Due to its low 
prevalence, it is necessary to have a high index of suspicion. The analytical data are usually 
nonspecific but have value in excluding other pathologies. Mild leukocytosis, anemia, or an 
increase in inflammatory markers might occur. A simple radiography, bone scan with tech-
netium 99 m, and CT are useful. Simple X-ray is of little use since it is usually normal. Bone 
scintigraphy provides much information, and the pattern of symmetrical sternoclavicular 
hypercaptation in “bull’s head” (where the sternal manubrium represents the skull and the 
sternoclavicular joints and the clavicles correspond to the horns) is very typical. CT provides 
us with a lot of information as it is the technique that best visualizes the joints of the anterior 
thoracic wall, showing a hyperostosis of this zone.
Biopsy and cultures of the affected joints are reserved for doubtful cases and to rule out other 
diagnostic possibilities. Imaging allows differential diagnosis with other processes (osteomy-
elitis, Paget’s disease, bone metastases, Tietze syndrome, other spondyloarthropathies).
In some patients, cutaneous manifestations might appear after years of nonspecific joint 
symptoms, making diagnosis even more difficult.
8. Evolution
SAPHO syndrome is a chronic disease that develops in form of outbreaks and remissions but 
in which radiological progression is slow [14]. Prognosis is usually good, but there are cases 
in which the pain that is produced is very intense and difficult to control it. Sometimes the 
onset of the disease could be acute and crippling. It has been observed that those factors such 
as female gender, anterior chest wall involvement, peripheral arthritis, skin lesions and eleva-
tion of acute phase reactants at onset of disease are related to the chronicity of the disease.
In a minority of patients, disease heals spontaneously or follows a chronically indolent course.
Complications are rare. Peripheral arthritis could become erosive in a minority of cases. 
Venous thrombosis could be observed due to an important disseminated inflammation from 
bones or joints to the adjacent tissue (especially as a result of clavicular hypertrophy), inflam-
matory masses in the anterior mediastinum, thoracic gorge syndrome that the swelling is 
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confused with a tumor (signs mainly observed at clavicular level), etc. Recurrent chronic mul-
tifocal osteomyelitis could cause permanent bone deformities, irregularities in limb length, 
and growth problems.
9. Treatment
With a little-known entity with few studies, this treatment is not protocolized [15] (Table 5). 
Nonsteroidal anti-inflammatory drugs (NSAIDs), sulfasalazine, systemic corticosteroids, col-
chicine, methotrexate, and antibiotics such as tetracyclines have been used with varying results.
NSAIDs and analgesics are used as a symptomatic treatment of disease. There is no NSAID 
that has shown to be more effective than other. Almost all patients receive NSAIDs, obtaining 
a good result, but due to recurrence, loss of efficacy, or progression of disease, it is necessary 
to establish other treatments.
As we have said before, it is believed that this disease might have an infectious origin, mainly 
Propionibacterium acnes, so several antibiotics have been used, although they have not been 
proved to be really effective. Tetracyclines have been shown to be effective in controlling 
severe forms of acne [16].
Immunosuppressants, such as sulfasalazine or methotrexate, have been used in cases resis-
tant to NSAIDs [17] and antibiotics, and although they have shown improvement in some 
patients, results have not been conclusive, and there are studies in this regard.
The use of bisphosphonates has been described as effective, although the majority of cases 
in which it has been used have been endovenous. Bisphosphonates are synthetic analogs 
of pyrophosphate; their function is to inhibit bone resorption by altering the function and 
metabolism of osteoclasts. Due to these properties, they have been used in treatment of pri-
mary and secondary osteoporosis, Paget’s disease, bone metastasis, and disorders of bone 
metabolism [18].
Pamidronate and zoledronic acid have been used. Pamidronate has been used at a dose of 
60 mg/day IV in a single dose, during a very short cycle of days in a row or repeating the 
dose several months later [19]. In most cases an improvement in pain and in the evolution of 
Symptomatic Modifier of disease
– Analgesics
– NSAIDs
– Glucocorticoids
– Calcitonin
– Antibiotics
– Sulfasalazine
– Methotrexate
– Leflunomide
– Bisphosphonates
– TNF antagonists
Table 5. SAPHO syndrome treatment.
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the disease was found. This is due to an action on bone remodeling that interferes with the 
production of proinflammatory cytokines.
Zoledronic acid is the most potent bisphosphonate and is usually used in hypercalcemias 
of tumoral origin. It has been used at a dose of 4 mg IV in a single dose with repetition at 
6 months if there was no improvement [20], obtaining good results (decrease in pain and 
regression of disease).
In the treatment with biological therapy, anti-tumor necrosis factor (TNF) drugs have been 
used with promising results.
Although NSAIDs usually control pain and inflammation, it is often necessary to use disease-
modifying drugs to improve symptoms. In this regard, it seems that IV bisphosphonates have 
been the most effective, but the dose and interval have not been unified.
Biological therapy also seems to show effectiveness [21]. More trials with these drugs would 
be needed to test their effectiveness against this disease and protocol the number of doses, the 
amount, and the interval between them.
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